The National Society of Genetic Counselors (NSGC) supports the U.S. Supreme Court's unanimous ruling in Association for Molecular Pathology v Myriad Genetics, Inc. which states that while synthetic complementary DNA is patent eligible, naturally occurring human DNA sequences may not be patented. NSGC believes that this ruling facilitates competitive pricing of genetic testing to benefit the public and supports both genomic medicine services and the development of novel ideas and technologies. (Reaffirmed - April 2019)

Back to Position Statements